Results 1 to 10 of about 15,844 (160)

Non-HLA Risk Loci ERBB3/IKZF4 and ERBB2/IKZF3/GSDMB/ORMDL3 Interact to Influence Progression of Autoimmunity in Relatives of T1D Patients. [PDF]

Diabetes Metab Res Rev
ABSTRACT Aim The genetic loci, ERBB2/IKZF3/GSDMB/ORMDL3 on chromosome 17q, and ERBB3/IKZF4 on chromosome 12q represent confirmed non‐HLA risk factors for the development of autoimmunity and progression to type 1 diabetes (T1D). It is unknown whether both regions can interact to influence the progression of T1D.
Mertens IM, Keymeulen B, Gorus FK, Van De Casteele M, Belgian Diabetes Registry.   +4 more
europepmc   +2 more sources

A Cohort Study on Cardiovascular Disease Mortality in Breast Cancer Patients With Different Subtypes. [PDF]

Breast J
Purpose To investigate cardiovascular disease (CVD) mortality among patients with different breast cancer (BC) subtypes to assess its implications for long‐term survival. Patients and Methods In total, 423,758 BC patients were included in this study utilizing data from the Surveillance, Epidemiology, and End Results 17 Registries Database (2010–2020 ...
Wang Z, Deng L, Wang P, Zhang Y, Shen Z.
europepmc   +2 more sources

Multiple System Atrophy (Cerebellar Type) With Overlapping Progressive Muscular Atrophy Features and Genetic Erb-B2 Receptor Tyrosine Kinase 4 (ERBB4) Amyotrophic Lateral Sclerosis Variant: A Case Report. [PDF]

Cureus
Multiple system atrophy (MSA) is a progressive disease with Parkinsonism, dysautonomia, and cerebellar symptoms wherein patients can present with a broad range of confusing and overlapping findings attributable to various neuroanatomical substrates.
Panganiban ELC, Rosales RL.
europepmc   +3 more sources

Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells [PDF]

Cancers, 2021
The epidermal growth factor receptor (EGFR) family member erb-b2 receptor tyrosine kinase 2 (ERBB2) is overexpressed in many types of cancers leading to (radio- and chemotherapy) treatment resistance, whereas the underlying mechanisms are still unclear. Autophagy is known to contribute to cancer treatment resistance.
Yongqiang Chen, Ruobing Wang, Shujun Huang, Elizabeth S. Henson, Jayce Bi, Spencer B. Gibson   +5 more
openaire   +2 more sources

Computer-aided scoring of erb-b2 receptor tyrosine kinase 2 (HER2) gene amplification status in breast cancer

Journal of Pathology Informatics, 2022
Identification of HER2 protein overexpression and/or amplification of the HER2 gene are required to qualify breast cancer patients for HER2 targeted therapies. In situ hybridization (ISH) assays that identify HER2 gene amplification function as a stand-alone test for determination of HER2 status and rely on the manual quantification of the number of ...
Alyson Yoder, Landon J. Inge, Chen-Chun Chen, Vijay R. Marati, Trung Kien Nguyen, Karel Zuiderveld, Jim Martin, Sarah Gladden, Mohammad Saleh Miri, Raghavan Venugopal, Bryan Lopez, Jim Ranger-Moore, Christoph Guetter   +12 more
openaire   +3 more sources

Multi-Omics Data Analysis Uncovers Molecular Networks and Gene Regulators for Metabolic Biomarkers

Biomolecules, 2021
The insulin-like growth factors (IGFs)/insulin resistance (IR) axis is the major metabolic hormonal pathway mediating the biologic mechanism of several complex human diseases, including type 2 diabetes (T2DM) and cancers. The genomewide association study
Su Yon Jung
doaj   +1 more source

MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer

Cell Death and Disease, 2022
The rapid onset of resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) limits its clinical utility in colorectal cancer (CRC) patients, and pan-erb-b2 receptor tyrosine kinase (ErbB) treatment strategy may be the ...
Yuanzhou Zhang, Shunshun Liang, Bowen Xiao, Jingying Hu, Yechun Pang, Yuling Liu, Juan Yang, Junpin Ao, Lin Wei, Xiaoying Luo   +9 more
doaj   +1 more source

Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer

The Journal of Molecular Diagnostics, 2022
Novel human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugates have demonstrated efficacy in HER2-low expressing breast cancers, which are currently defined as those with immunohistochemistry (IHC) scores of 1+ or 2+ with a negative in situ hybridization assay. However, current HER2 testing methods are designed to identify HER2-
Keying Xu, Jane Bayani, Elizabeth Mallon, Gregory R. Pond, Tammy Piper, Annette Hasenburg, Christos J. Markopoulos, Luc Dirix, Caroline M. Seynaeve, Cornelis J.H. van de Velde, Daniel W. Rea, John M.S. Bartlett   +11 more
openaire   +3 more sources

The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma [PDF]

Türk Patoloji Dergisi, 2017
Objective: Chordoma is a rare malignant bone tumor with a poor outcome. Although radiotherapy and gamma knife surgery have been used for treatment, providing a cure for the tumor is not easy, because of the frequent recurrences.
Zeynep TOSUNER, Zeynep TOSUNER, Türker KILIÇ, Baran YILMAZ   +3 more
doaj   +1 more source

Conditional ERK3 overexpression cooperates with PTEN deletion to promote lung adenocarcinoma formation in mice

Molecular Oncology, 2022
ERK3, officially known as mitogen‐activated protein kinase 6 (MAPK6), is a poorly studied mitogen‐activated protein kinase (MAPK). Recent studies have revealed the upregulation of ERK3 expression in cancer and suggest an important role for ERK3 in ...
Sreeram Vallabhaneni, Jian Liu, Marion Morel, Jixin Wang, Francesco J. DeMayo, Weiwen Long   +5 more
doaj   +1 more source